The OncLive Disparities in Cancer Care condition center page is a comprehensive resource for clinical news and expert insights on disparities in care with regards to race, gender, demographics, geographics, and socioeconomic status. This page features news articles, interviews in written and video format, and podcasts that focus on studies evaluating these various disparities and how they impact clinical trial enrollment and oncology treatment.
October 27th 2024
Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
NCCN Launches Health Equity Report Card to Address Racial Disparities in Cancer Care
The National Comprehensive Cancer Network has partnered with the American Cancer Society Cancer Action Network and the National Minority Quality Forum to launch the new Health Equity Report Card pilot program to address structural and interpersonal bigotry that results in disparities in cancer care and outcomes.
Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer
Daniel King, MD, PhD, discusses the results of an institutional review evaluating socioeconomic factors associated with disparities for germline genetic testing in patients with pancreatic adenocarcinoma, why germline testing is necessary for thi population, and how he is addressing gaps in germline testing in his own practice.
PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent
The risk for developing hepatocellular carcinoma appears to increase with subsequent generations for Americans of Mexican descent, according to findings from a study of US-born Hispanics/Latinos living in Los Angeles, California.
Older Patients of Color With Cancer Less Likely to Receive Opioids at End of Life
Results from a study of 318,549 Medicare beneficiaries with poor-prognosis cancers showed than Black and Hispanic patients were substantially less likely to receive any opioids or long-acting opioids than White patients at the end of life.
Stark Differences in Mortality Rates Emphasize Ongoing Racial Disparities in Breast Cancer
Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.
CCNE1 Amplifications Tied to Racial Disparities in Serous Endometrial Cancer Outcomes
Julian Schink, MD, discusses a study evaluating racial differences in the mutational landscape of serous endometrial cancer, underscores the need for appropriate genomic testing and treatment for Black women with the disease, and explains the importance of racial representation across clinical trials.
Advances in Site Self-Assessment Tools Aim to Bolster Equity in Clinical Trials
National Cancer Institute-designated comprehensive cancer centers routinely perform clinical trial site self-assessments. However, participation in these types of assessments is far less commonplace among community oncology sites.
Retrospective Analysis Highlights Disparities in Germline Testing in Prostate Cancer
August 2nd 2022Carrie Horton, MS, CGC, discusses how the findings from a retrospective analysis of germline testing rates among racially diverse groups of men with prostate cancer will guide future research and influence the steps community oncologists can take to increase testing rates.
ASCO, ACCC Issue Recommendations to Boost Clinical Trial Diversity
The American Society of Clinical Oncology and the Association of Community Cancer Centers have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.
Survival is Significantly Poorer for Young Black Patients With AML Compared With White Counterparts
Despite receiving similar treatment, Black patients between the ages of 18 and 29 years with acute myeloid leukemia were twice as likely to die within 5 years compared with Whites.
Women in Oncology: How Leukemia Treatment has Changed and Stayed Stagnant Over the Years
July 8th 2022Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.
New USPSTF Guidelines Increase Lung Cancer Screening Among African Americans
The US Preventive Services Task Force updated its lung cancer screening guidelines in 2021 to include more members of vulnerable populations, including African Americans, women, and the LGBTQ community.
Black Patients Less Likely to Participate on Clinical Trials in Breast Cancer
May 26th 2022Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.